# A Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous SPM 927

> **NCT00800215** · PHASE2 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 60 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** iv SPM 927 and oral placebo tablet
- **DRUG:** oral SPM 927 tablet and iv placebo
- **DRUG:** iv SPM 927 and oral placebo tablet
- **DRUG:** oral SPM 927 tablet and iv placebo

## Key facts

- **NCT ID:** NCT00800215
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03-04
- **Primary completion:** 2004-08-17
- **Final completion:** 2004-11-30
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00800215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00800215, "A Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous SPM 927". Retrieved via AI Analytics 2026-09-17 from https://api.ai-analytics.org/clinical/NCT00800215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*